We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


#AskDrDurie is the IMF’s weekly web series, hosted by IMF Chairman Dr. Brian Durie, which answers questions of broad audience interest about myeloma. If you have a question that might be of interest to the general myeloma community, please send it to AskDrDurie@myeloma.org for consideration. Thank you!

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
previous     next      view all

12.03.14   #AskDrDurie: What's new at ASH 2014

In this week’s special #AskDrDurie episode, Dr. Brian Durie of the IMF takes a look at the December 2014 ASH (American Society of Hematology) meeting in San Francisco. He previews what abstracts will be presented and talks about news to expect out of the meeting.


11.19.14   #AskDrDurie: Can Cytoxan cause heart damage?

In this week's #AskDrDurie, the IMF's Dr. Brian G.M. Durie answers a patient's concern regarding myeloma treatment and heart damage--specifically when it comes to the drug Cytoxan.


11.13.14   #AskDrDurie: What happens to stem cells once they are harvested?

In this week's episode of #AskDrDurie, Dr. Brian G.M. Durie of the IMF answers a patient's question regarding stem cells. If they are harvested in a specific facility, can they be moved and stored elsewhere later?
 
Find out the answer in this video!


11.06.14   #AskDrDurie: Can the Hevylite™ test be used to monitor IgA myeloma?

In this week’s episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a patient question regarding IgA myeloma and tests used to monitor it, specifically the Hevylite™ test. Watch this video to learn all about Hevylite.


10.30.14   #AskDrDurie: Is it possible to have short remissions without high-risk features?

Inspired by last week's #AskDrDurie episode in which Dr. Brian Durie of the IMF explained the definition of remission when it comes to  myeloma patients, this new episodes is a follow-up. Here, Dr. Durie explains why a myeloma patient might experience a short remission period, even if high-risk features have not been identified.


10.23.14   #AskDrDurie: What is remission?

In the latest episode of #AskDrDurie, Dr. Brian Durie of the IMF explains what remission means for myeloma patients.


10.16.14   #AskDrDurie: How does the IMF contribute to the myeloma community?

In the latest episode of #AskDrDurie, Dr. Brian Durie addresses a patient who has just learned about the IMF by explaining three key contributions the IMF makes to myeloma research and education.


09.25.14   #AskDrDurie: What is Selinexor

In this week's episode of #AskDrDurie, Dr. Brian Durie of the IMF takes a question from a patient who has relapsing myeloma and is wondering about the new drug Selinexor. Dr. Durie explains what the drug is and how it can be used in myeloma.


09.18.14   #AskDrDurie: Is autologous stem cell transplant still recommended?

In this episode of the IMF’s #AskDrDurie web series, Dr. Brian Durie talks about when and for what kind of myeloma patient an autologous stem cell transplant (ASCT) is recommended.


09.10.14   #AskDrDurie: Has there been any change in recommendations used to treat bone disease in myeloma?

In this week's episode of #AskDrDurie, the IMF's Chairman Dr. Brian Durie answers a patient's question regarding how bone disease in myeloma is treated. He discusses bisphosphonates such as Aredia and Zometa and what the current recommendations are.


previous     next      view all